New immune therapy shows promise in early leukemia trial

NCT ID NCT05470140

Completed Disease control Sponsor: Wugen, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The goal was to check safety and find the best dose. Participants received immune cells designed to attack cancer. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Norton Health Care

Louisville, Kentucky, 40299, United States
Peter MacCallum Cancer Center

Melbourne, Australia
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Royal Perth Hospital

Perth, Australia
Royal Prince Alfred Hospital

Sydney, Australia
Stanford Healthcare

Palo Alto, California, 94304, United States
University of Maryland

Baltimore, Maryland, 21201, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.